Patents by Inventor Robert Epple

Robert Epple has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230365571
    Abstract: The present invention relates to tricyclic compounds comprising a diazepinone moiety which are effective in inhibiting Sppl2a (signal peptide peptidase like protease 2a), to pharmaceutical compositions containing such inhibitors, and to methods of using such inhibitors and compositions.
    Type: Application
    Filed: September 15, 2021
    Publication date: November 16, 2023
    Inventors: Trixi Brandl, Claus Ehrhardt, Robert Epple, Christian Markert, Pascal Rigollier, Juraj Velcicky
  • Publication number: 20220127247
    Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.
    Type: Application
    Filed: February 4, 2020
    Publication date: April 28, 2022
    Inventors: Mihai AZIMIOARA, Bei CHEN, Robert EPPLE, James Paul LAJINESS, Casey Jacob Nelson MATHISON, Juliet NABAKKA, Victor Ivanovich NIKULIN, Sejal PATEL, Dean Paul PHILLIPS, Paul Vincent RUCKER, Andrew VALIERE, Baogen WU, Shanshan YAN, Xuefeng ZHU
  • Publication number: 20220033407
    Abstract: The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.
    Type: Application
    Filed: December 13, 2019
    Publication date: February 3, 2022
    Inventors: Mihai D. Azimioara, Bei Chen, Robert Epple, Declan Hardy, Ayako Honda, Philip Lam, Hasnain Ahmed Malik, Fabio Meier, Truc Ngoc Nguyen, Barun Okram, Sejal Patel, Rodrigo Rodriguez, Duncan Shaw, Yiping Shen, Baogen WU
  • Patent number: 11066369
    Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: July 20, 2021
    Assignee: Novartis AG
    Inventors: Mihai Azimioara, Bei Chen, Robert Epple, Ayako Honda, Philip Lam, Hasnain Ahmed Malik, Casey Jacob Nelson Mathison, True Ngoc Nguyen, Victor Ivanovich Nikulin, Sejal Patel, Dean Paul Phillips, Rodrigo A. Rodriguez, Baogen Wu, Xuefeng Zhu
  • Publication number: 20200002281
    Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.
    Type: Application
    Filed: September 10, 2019
    Publication date: January 2, 2020
    Inventors: Mihai Azimioara, Bei Chen, Robert Epple, Ayako Honda, Philip Lam, Hasnain Ahmed Malik, Casey Jacob Nelson Mathison, Truc Ngoc Nguyen, Victor Ivanovich Nikulin, Sejal Patel, Dean Paul Phillips, Rodrigo A. Rodriguez, Baogen Wu, Xuefeng Zhu
  • Patent number: 10450273
    Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: October 22, 2019
    Assignee: Novartis AG
    Inventors: Mihai Azimioara, Bei Chen, Robert Epple, Ayako Honda, Philip Lam, Hasnain Ahmed Malik, Casey Jacob Nelson Mathison, Truc Ngoc Nguyen, Victor Ivanovich Nikulin, Sejal Patel, Dean Paul Phillips, Rodrigo A. Rodriguez, Baogen Wu, Xuefeng Zhu
  • Publication number: 20180072673
    Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.
    Type: Application
    Filed: August 28, 2017
    Publication date: March 15, 2018
    Applicant: Novartis AG
    Inventors: Dean Paul Phillips, Mihai AZIMIOARA, Bei CHEN, Robert EPPLE, Victor Ivanovich NIKULIN, Rodrigo A. RODRIGUEZ, Sejal PATEL, Ayako HONDA
  • Patent number: 9440957
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: September 13, 2016
    Assignee: Novartis AG
    Inventors: Gerald Lelais, Robert Epple, Thomas H. Marsilje, III, Pierre-Yves Michellys, Matthew McNeill, Yun Long, Wenshuo Lu, Bei Chen, Badry Bursulaya, Songchun Jiang
  • Publication number: 20150197505
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Application
    Filed: June 5, 2013
    Publication date: July 16, 2015
    Applicant: IRM LLC, A Delaware Limited Liability Company
    Inventors: Gerald Lelais, Robert Epple, Thomas H. Marsilje, III, Pierre-Yves Michellys, Matthew McNeill, Yun Long, Wenshuo Lu, Bei Chen, Badry Bursulaya Bursulaya, Songchun Jiang
  • Publication number: 20150152083
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Application
    Filed: June 5, 2013
    Publication date: June 4, 2015
    Applicant: IRM LLC, A Delaware Limited Liability Company
    Inventors: Gerald Lelais, Robert Epple, Pierre-Yves Michellys, Badry Bursulaya, Songchun Jiang, Thomas H. Marsilje III, Matthew MCneill
  • Patent number: 8575168
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: November 5, 2013
    Assignee: IRM LLC
    Inventors: Mihai Azimioara, Christopher Cow, Robert Epple, Gerald Lelais, John Mecom, Victor Nikulin
  • Patent number: 8394841
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating G protein-coupled receptor 120 (GPR120), and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated GPR120.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: March 12, 2013
    Assignee: IRM LLC
    Inventors: Robert Epple, Mihai Azimioara, Christopher Cow, Ross Russo, Victor Nikulin, Gerald Lelais
  • Patent number: 8362050
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by G protein-coupled receptors, in particular G protein-coupled receptor 120.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: January 29, 2013
    Assignee: IRM LLC
    Inventors: Xiaohui He, Xuefeng Zhu, Kunyong Yang, Robert Epple, Hong Liu
  • Patent number: 8334288
    Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent; diseases or disorders associated with the activity of GPR119.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: December 18, 2012
    Assignee: IRM LLC
    Inventors: Robert Epple, Gerald Lelais, Victor Nikulin, Lucas Westcott-Baker
  • Patent number: 8258156
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: September 4, 2012
    Assignee: IRM LLC
    Inventors: Phillip B. Alper, Mihai Azimioara, Christopher N. Cow, Robert Epple, Pierre-Yves Michellys, Victor Nikulin
  • Publication number: 20120196844
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: March 16, 2012
    Publication date: August 2, 2012
    Applicant: IRM LLC
    Inventors: Phillip B. Alper, Mihai Azimioara, Christopher Cow, Robert Epple, Songchun Jiang, Gerald lelais, Pierre-Yves Michellys, Daniel Mutnick, Victor Nikulin, Lucas Westcott-Baker
  • Patent number: 8153635
    Abstract: The invention provides compounds of Formula I: wherein A, L, m, q, Q, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention. The invention further provides for pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: April 10, 2012
    Assignee: IRM LLC
    Inventors: Phillip B. Alper, Mihai Azimioara, Christopher Cow, Robert Epple, Songchun Jiang, Gerald Lelais, Pierre-Yves Michellys, Daniel Mutnick, Victor Nikulin
  • Publication number: 20110263557
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119; such as, but not limited to, diabetes, obesity and associated metabolic disorders. Formula (I) is a compound, in which A can have up to 2 ring —CH2- group substituted with —C(O)— and can be partially unsaturated with up to 2 double bonds; Wi and W2 are independently selected from CR10 and N; wherein R10 is selected from hydrogen and C1_6alkyl; Yi is selected from NRn, O and S; wherein Rn is selected from hydrogen and C1_6alkyl; Y2 and Y3 are independently selected from CH and N; Y4 is selected from CH2, OCH2 and NR15; wherein R15 is selected from hydrogen and C1_6alkyl; or the pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 27, 2011
    Applicant: IRM LLC
    Inventors: Christopher Cow, Robert Epple
  • Publication number: 20110245220
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: October 1, 2010
    Publication date: October 6, 2011
    Applicant: IRM LLC
    Inventors: Mihai Azimioara, Christopher Cow, Robert Epple, Gerald Lelais, John Mecom, Victor Nikulin
  • Publication number: 20110224185
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: May 23, 2011
    Publication date: September 15, 2011
    Inventors: Phillip B. Alper, Mihai Azimioara, Christopher Cow, Robert Epple, Songchun Jiang, Gerald Lelais, Pierre-Yves Michellys, Daniel Mutnick, Victor Nikulin, Lucas Westcott-Baker